EcoDrugPlus

60s Ribosomal Protein L10

Ensembl ID : ENSLCAG00010004182
Gene Symbol: LOC108887522
4 Cross references
396 Possible Orthologues:

60s Ribosomal Protein L12

Ensembl ID : ENSLCAG00010004367
Gene Symbol: LOC108894289
4 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSLCAG00010001161
Gene Symbol: LOC108901706
4 Cross references
328 Possible Orthologues:

60s Ribosomal Protein L5

Ensembl ID : ENSLCAG00010008424
Gene Symbol: LOC108878938
4 Cross references
455 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSLCAG00010024507
Gene Symbol: LOC108878154
4 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSLCAG00010005729
Gene Symbol: ABL1
4 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSLCAG00010026090
Gene Symbol: ADAM17
4 Cross references
210 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSLCAG00010022846
Gene Symbol: ADAM17A
1 Cross references
208 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSLCAG00010026928
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSLCAG00010016772
Gene Symbol: ADRM1
2 Cross references
191 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSLCAG00010026591
Gene Symbol: LOC108887425
4 Cross references
194 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSLCAG00010011782
Gene Symbol: AKT1
4 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).